There is no cure for MS today. More than 20 approved drugs can sharply cut relapses, but slow, "smoldering" damage keeps worsening disability for many people. Our view: a cure will need three things: a reset of the immune system, drugs that reach inflammation hidden inside the brain, and repair of lost myelin. Stopping the Epstein-Barr virus could prevent MS altogether.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with a neurologist, ideally an MS specialist.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neurologist.
Could myelin-repair drugs have struggled partly because they were given while lesions were still smoldering? If a brain-reaching drug first quieted rim lesions on MRI, would a repair drug (none is approved yet) then rebuild more myelin in those lesions than it does alone?
What would prove it wrong: if quieted rim lesions show no more myelin repair with a repair drug than without one.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
This was an extra analysis of a 16-week randomized trial of a low-fat diet versus usual diet. Only 27 people had complete data (16 on the diet, 11 on their usual diet). Changes in fatigue scores lined up with shifts in fatty acid and amino acid chemicals in the blood, and several blood fats fell on the diet but rose in the usual-diet group. The authors call the findings preliminary and say larger trials are needed. It does not show that diet treats MS.
In 2,007 adults with relapsing MS, relapse rates were 35.2% lower (0.073 vs 0.112 a year) in REMODEL-1 and 31.2% lower (0.080 vs 0.116) in REMODEL-2 than with teriflunomide. New or growing MRI lesions were about 65% to 70% lower. The risk of 6-month confirmed disability worsening was 29.2% lower, but that result was only nominally significant. Liver enzyme rises above 3 times normal occurred in 2.0% vs 7.4%, with no liver safety signal. Novartis (the maker) plans to seek approval; it is not approved for MS.
Genentech reported new analyses of its ongoing Phase 3 trials. Against teriflunomide in relapsing MS, fenebrutinib cut relapses by 55%, yearly brain volume loss by 23% and the risk of confirmed disability progression by 16%, and 75% had no sign of disease activity at nearly two years. These are company-reported conference data that have not been peer reviewed. The FDA is still reviewing the drug.
An Italian records review of 30 adults found that some paramagnetic rim lesions, a sign of chronic inflammation on MRI, disappeared after a stem-cell transplant (5 of 26 in one group, 10 of 20 in the other). The study was small, had no control group and follow-up times varied, so it does not show the transplant causes this.
In 187 people ages 10 to 17 with relapsing MS, IV ocrelizumab was "noninferior" to fingolimod pills for relapses (rate ratio 0.52, but the range of possible values was wide: 0.19 to 1.33). New or growing MRI lesions were lower with ocrelizumab (rate ratio 0.52, p = .001). Infusion reactions affected 48.4%, mostly mild or moderate. The trial was short and the MRI results were secondary endpoints. Presented at the Child Neurology Society meeting, Oct 14-17.
In 182 people treated for two years, 50.5% had no sign of disease activity at week 48 (95% had no relapse). Open-label, with no comparison group.
A new Atlas of MS report in Multiple Sclerosis Journal counts 3.1 million people in 2024, up from 2.8 million in 2020. Researchers say better diagnosis may explain part of the rise.
First BTK inhibitor filed in both relapsing and primary progressive MS.
After aHSCT, inflammation and nerve-damage markers in blood and spinal fluid stayed low for years, consistent with lasting disease quiet.
Interim results from this UK trial of existing drugs in progressive MS found that alpha-lipoic acid shows early promise, so it moves to a larger second stage that tracks disability. This is an early look, not proof. Final results for the lipoic acid stage are expected in 2029, and people should not try to get lipoic acid outside a trial.
Phase 1b/2 trial of C-CAR168, a CAR-T therapy that targets two B-cell markers (CD20 and BCMA), in people whose progressive MS didn't respond to other treatment.
Lower relapse rates and fewer MRI lesions than teriflunomide in ~2,000 adults with relapsing MS, with no liver safety signal.
63% had a meaningful drop in depression with cognitive behavioral therapy versus 33% with supportive listening. A small trial (60 people).
51.1% and 58.5% fewer relapses than teriflunomide. Matched Ocrevus on disability progression in primary progressive MS.
Long-term extension in relapsing MS: no new safety concerns and consistently low disease activity.
First medicine approved for non-relapsing secondary progressive MS in Europe, with mandatory liver monitoring.
About 32 patients treated so far. Disability improved in 8 of 12 who could be evaluated. Cytokine release syndrome, an immune overreaction, occurred in 62.5%, mostly mild.
The complete response letter cited severe drug-induced liver injury, including a death, and unclear benefit for many patients.
180 adults diagnosed with relapsing MS in the last two years receive vaccine or placebo over six months.
The United Arab Emirates became the first country to approve a drug for non-relapsing secondary progressive MS.
Relapsing MS can often be brought almost to a standstill. 2026's breakthroughs are oral drugs that reach inside the brain, the first to slow progression without relapses.
The first drug for people whose MS worsens without relapses. In the HERCULES trial it cut the risk of 6-month disability progression by 31%. The FDA turned it down in December 2025 over severe liver injury, including one death, so strict liver monitoring is required in Europe.
Cut relapses by 51–59% versus teriflunomide, and matched Ocrevus at slowing disability in primary progressive MS. It's an Ocrevus-level result from a pill, and the first BTK drug filed for both forms.
Beat teriflunomide on relapses and MRI lesions in about 2,000 adults, with no liver safety signal. Full data came out Oct 23 at MSToronto and in The Lancet: relapse rates 31% to 35% lower. Novartis plans global filings; not yet approved for MS.
Chemotherapy wipes out the immune system, which then regrows from the patient's own stem cells. In one series of 145 patients, 80% had no disease activity at 2 years and 68% at 4 years. It carries real risks, so it's reserved for aggressive MS.
Disability scores improved in 8 of 12 evaluable patients. Two people with secondary progressive MS stayed in drug-free remission at 12 and 6 months. The FDA cleared a Phase 1b/2 trial in September 2026.
Tests whether a vaccine that stops Epstein-Barr virus from reactivating can reduce MS activity. If it works, the same idea could one day prevent MS.
| Treatment | For | What it does |
|---|---|---|
| Interferons, glatiramer (from 1993) | Relapsing MS | The first MS drugs. Modest relapse reduction, long safety record. |
| Oral drugs (fingolimod, teriflunomide, dimethyl fumarate, cladribine, siponimod and others) | Relapsing MS | Pills that block or trap immune cells. Moderate to high effect. |
| Anti-CD20 antibodies (ocrelizumab, ofatumumab, ublituximab) | Relapsing MS; ocrelizumab also primary progressive | Remove B cells. Among the most effective options. |
| Natalizumab, alemtuzumab | Highly active MS | Very effective, with serious-risk monitoring. |
| Steroids | Relapses | Speed recovery from an attack. They don't change the long-term course. |
No supplement cures MS. Vitamin D, exercise and not smoking have the best support. Some popular supplements can cause real problems. We rate each by the strength of human evidence.
Low levels are linked to higher MS risk and more activity, and recent trials in very early MS suggest high doses may reduce new activity. Have your level checked and dose it with your doctor.
Smoking raises the risk of getting MS and of faster progression. Quitting is one of the strongest steps a person can take.
Obesity in adolescence is linked to higher MS risk later, especially in people with genetic risk.
Improves fatigue, strength, mood and walking. Benefits look largest in the first five years after diagnosis. A September 2026 study found even 20-minute walks improved brain connectivity.
A small 2026 study found bright-light glasses reduced fatigue within days. It's promising, but early.
Some people feel better, but trials are small and don't show the diets change the disease. A balanced, plant-rich diet is reasonable.
Both were tested in large progressive-MS trials and didn't slow disability.
Be careful: high-dose biotin can make blood tests give false results, including thyroid and heart tests. Overseas "stem cell" clinics that aren't part of a regulated trial can be dangerous and costly. Tell your neurologist about everything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
Named a Center for Comprehensive MS Care by the National MS Society in March 2026.
Says it was the first program in Michigan to earn the National MS Society's Center for Comprehensive MS Care designation.
Two Northwestern hospitals are recognized by the National MS Society as Centers for Comprehensive Care.
Designated a Center for Comprehensive MS Care by the National MS Society in December 2021.
Recognized by the National MS Society as a Center for Comprehensive MS Care in a November 2023 announcement.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face MS alone. These groups connect patients, families and caregivers with people who understand. Most are free.
Virtual groups, the MSFriends® phone program, Discord communities and one-on-one peer connections.
Get connected ↗An independent social network founded by people with MS, open worldwide.
Join ↗A free social network with interest groups and medically reviewed articles.
Join ↗The Multiple Sclerosis Association of America's online forum and support programs.
Visit MSAA ↗The UK MS Society's active community forum.
Visit forum ↗Themed Zoom groups led by volunteers who live with MS.
Learn more ↗A large, open Reddit community for people with MS.
Open on Reddit ↗Many MS groups. This link searches Facebook (a login is required).
Search Facebook ↗The National MS Society also offers MSFriends®, free one-to-one phone support from volunteers who have MS.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
The biggest 2026 split: Europe and the UAE approved the first drug for progressive MS without relapses, while the FDA refused it over liver safety. Some European centers also use stem-cell transplants more readily.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Interferons, glatiramerRelapsing MS | 1993 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Ocrelizumab (Ocrevus)Relapsing & primary progressive | 2017 | 2018 | Yes | Yes | — | — | — | Yes | Yes |
| Tolebrutinib (Cenrifki)Non-relapsing SPMS | Rejected 2025 | 2026 | — | — | — | — | — | — | — |
| FenebrutinibRelapsing & primary progressive | Priority review | — | — | — | — | — | — | — | — |
| RemibrutinibRelapsing MS | Filing planned | Filing planned | — | — | — | — | — | — | — |
European regulators decided the benefit outweighed the liver risk, with mandatory monitoring. The FDA disagreed. People with non-relapsing SPMS now have a treatment option in Europe that U.S. patients don't.
The United Arab Emirates approved it ten months before Europe, the first approval anywhere for progressive MS without relapses.
European MS and transplant societies issued joint guidance on using aHSCT for highly active relapsing MS. In the U.S. it's still largely done through trials such as BEAT-MS.
MS is an autoimmune disease: the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. The strongest trigger found so far is the Epstein-Barr virus, acting on top of genes and lifestyle.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help people affected by MS pay for care, equipment and costs. Funds are limited and rules vary, so contact each one directly.
A one-time grant toward an urgent rent or utility bill. Because funding is limited, it currently takes only applicants with a final eviction or shut-off notice, for requests up to $400. Its copay help is suspended.
See the program ↗May help find, partly pay for or fully pay for a device such as a mobility or seating aid, home or vehicle change, communication aid or cooling aid. The page lists no amounts.
See the program ↗Pays reasonable paratransit fees, and through Lyft and Uber can pay for rides to neurologist visits and infusion centers. Restrictions may apply.
See the program ↗Sends cooling vests and accessories free of charge to people with MS who qualify, once every five years.
See the program ↗Provides products for safety, mobility and daily living, plus some exercise items, free of charge to people with MS who qualify. MSAA says it does not give cash for bills or prescriptions.
See the program ↗Helps pay for brain and neck MRI scans for people who are uninsured or can't afford their insurance costs. It does not repay costs already paid, and approval takes 30 to 45 days.
See the program ↗Grants toward therapies insurance often doesn't cover, such as acupuncture or fitness programs, and toward emergency medical bills, large copays and medicines not fully covered. The page gives no amounts.
See the program ↗Quality of Life grants of up to $1,000 per person each year for mobility equipment, safety aids, assistive technology and cooling vests. Funding is limited, and it does not pay for items already bought, medicines or bills.
See the program ↗Helps pay medicine copays, coinsurance, deductibles and insurance premiums. The fund was listed as open on October 6, 2026, but funds can close.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The vitamin D, smoking, teen-obesity, diet, biotin and simvastatin summaries, the drug-approval years in the standard-treatment table, and the biotin lab-test warning reflect the established published record and FDA safety communications. They don't yet have individual citations here. Expert care centers: The National MS Society's center finder could not be opened, so designations come from each center's own announcement (two are dated 2021 and 2023 and may have been renewed or changed). No verified center outside the U.S. was found. Financial help: checked October 6, 2026. The MS Focus and MSAA pages do not state a country, but their forms and income rules are U.S.-based; MSAA's income limit comes from its FAQ page. MS, I'mpossible is a young charity (2024) that gives no award amounts. The National MS Society was not listed because no direct-aid program page could be found, and MS Society UK has permanently closed its national grants. HealthWell's MS fund was closed to new patients that day.